Ask AI

Disease Modification in Alzheimer’s Disease: Current Evidence, Clinical Practice, and Emerging Directions

The emergence of disease-modifying therapies has transformed the treatment landscape for Alzheimer’s disease, introducing new opportunities and challenges in clinical practice. Learners will review current evidence for available therapies, including lecanemab and donanemab, and explore patient selection, safety considerations, and emerging therapeutic approaches that may shape the future of Alzheimer’s disease management.

Share

Program Content

Events

  • Live Event
    Disease Modification in Alzheimer's Disease: Current Evidence, Clinical Practice, and Emerging Directions
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Disease Modification in Alzheimer's Disease
Disease Modification in Alzheimer's Disease: Current Evidence, Clinical Practice, and Emerging Directions
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.